To compare the incidence of postoperative de novo voiding dysfunction and to identify the risk factors affecting the development of de novo voiding dysfunction after various midurethral sling (MUS) procedures for female stress urinary incontinence (SUI Cases were reviewed retrospectively with follow-up of at least 6 months. The subjects were divided into 2 groups according to the presence of postoperative de novo voiding dysfunction. De novo voiding dysfunction was defined as a low maximal uroflow rate (Qmax＜15 ml/s) or a large post-voided residual urine volume (PVR＞100 ml) observed at 6 months postoperatively. Clinical and urodynamic parameters were compared between the voiding dysfunction (Group I) and normal voiding (Group II) groups according to MUS procedure. Results: Of the 625 subjects, 163 (26%) patients showed evidence of de novo voiding dysfunction (Group I). Of these 163 subjects, 12 (7.3%) patients complained of voiding symptoms. There was no difference in the incidence of de novo voiding dysfunction according to MUS procedure. Multivariate analysis showed Qmax to be the only independent risk factor for de novo voiding dysfunction.
INTRODUCTION
The midurethral sling (MUS) procedure became one of the standard minimally invasive procedures used to treat stress urinary incontinence (SUI) since tension-free vaginal tape (TVT Ⓡ ) was first described in 1996 by Ulmsten. [1] [2] [3] [4] Shortly thereafter, a different method of tape insertion was described, in which the tape passes through the obturator foramen (transobturator tape, or TOT Ⓡ ). Several variations of this method have been introduced to reduce complications such as bladder perforation. 5 In MUS, the sling provides dynamic kinking of the urethra when abdominal pressures increase but not at the resting phase.
Thus, theoretically, MUS does not cause voiding dysfunction such as weak stream, urinary hesitancy, and straining voiding in itself. However, voiding dysfunction such as a decreased maximal uroflow rate (Qmax) or increased post-voided residual urine volume (PVR) has been reported after the MUS operation. 3, 6 Although a standard definition of female voiding dysfunction is controversial, 7 Qmax, PVR, and voiding time are used as criteria for voiding dysfunction. 3, 8, 9 The incidence of voiding dysfunction after MUS has been reported to be between 4% and 55% and it may affect the patient's well-being and quality of life (QoL), consequently decreasing patient satisfaction with the procedure.
2,3,10
Postoperative voiding dysfunction can be self-limiting if urinary symptoms do not exist and the PVR is adequate. 1, 11 However, in some severe cases, unavoidable removal or relaxation of the mesh has been reported. 12, 13 The incidence and risk factors of de novo voiding dysfunction after the MUS procedure in patients with normal voiding function preopera-
tively have yet to be evaluated. The aim of the present study was therefore to evaluate the incidence and risk factors of de novo voiding dysfunction after the MUS procedure and to compare these according to type of MUS device. Postoperative evaluation was done at 3 and 6 months after the MUS procedure. All patients were followed up with voiding symptom history, physical examination, uroflowmetry, voiding diary, and a validated questionnaire to assess the patient's perception of the results of and satisfaction with the surgery.
MATERIALS AND METHODS
Cure of SUI was defined as complete dry and improvement as still urine leakage but no treatment required or patient satisfied with the results of the operation. Cure and improvement were regarded as successful treatment of SUI. Independent-sample t-tests and Pearson's chi-square test were used to test the statistical significance of differences between patients with and without postoperative voiding dysfunction.
Logistic regression analysis was used to explore the risk factors of postoperative Qmax decrease. Statistical significance was considered at p＜0.05.
RESULTS
A total of 631 patients underwent the MUS procedure during this period. Among them, 4 patients with a preoperative Qmax ＜15 ml/s and 2 patients with postoperative urinary retention were excluded. The analysis was therefore based on 625 patients. Bladder perforation occurred in 2 patients, which was treated with urethral catheterization. The urethral catheter was removed after confirmation of no urine leakage on a cystogram after 1 week.
The mean age of the study population was 51.6 (range, 31-96) years and parity was 2.5 (range, 0-9 ml/s or PVR＞100 ml. All 3 with weak stream had a Qmax ＜15 ml/s with PVR＞100 ml. Two patients with residual urinary sensation had a Qmax＜15 ml/s. Among the 18 patients with PVR＞100 ml, 7 patients had PVR＞200 ml, requiring intermittent catheterization. One of them presented with a large amount (308 ml) of PVR and was treated with postvoid catheterization without symptom improvement; therefore, the tape was released at 5 months after the MUS procedure. Meanwhile, 132 patients in whom postoperative Qmax decreased to ＜15 ml/s showed no voiding symptoms, and among these, only 9 patients presented with residual urine volume over 100 ml.
In the comparative analysis of preoperative parameters between the normal voiding group (group 2) and the voiding dysfunction group (group 1) postoperatively, preoperative
Qmax was significantly lower in group 1 than in group 2 (p= 0.294; 21.3±11.7 ml/s in group 1 and 25.2±10.2 ml/s in group 2, respectively) ( Table 1 ). The other variables such as surgical methods, age, BMI, parity, DM, cystocele, and urodynamic variables did not differ significantly between groups. The mean change in Qmax (postoperative Qmax-preoperative Qmax) was significantly greater in group 1 than in group 2.
To explore the risk factors for postoperative de novo voiding dysfunction, multiple logistic regression was performed and preoperative Qmax was found to be the only risk factor. As the preoperative Qmax increased by 1 ml/s, the risk of postoperative voiding dysfunction decreased by a factor of 0.95 (Table 2 ). The other variables such as age, BMI, and parity did not show statistical differences in the multiple regression analysis.
DISCUSSION
MUS is the single most common surgical modality for the treatment of SUI, with good results and few complications. In MUS, the sling provides dynamic kinking of the urethra when abdominal pressures increase, while maintaining stability at the resting phase, consequently preventing urinary incontinence. 7, 17, 18 It is commonly agreed that MUS compresses the midurethra, thus affecting voiding during the emptying phase.
Our study showed the cure and improvement rate of SUI to be 76.1% and 21.4%, respectively, which is similar to the results of other studies. 19, 20 In our study, postoperative evaluation was performed at least 6 months after the MUS procedure.
Qmax was significantly decreased postoperatively, but the voided volume and PVR showed no significant changes. 
CONCLUSIONS
In our study, a considerable rate of postoperative de novo voiding dysfunction, although mostly asymptomatic, did exist.
Preoperative peak flow rate was regarded as the only risk factor for postoperative de novo voiding dysfunction. There were no differences in the incidence according to method of MUS. In patients with low preoperative Qmax, the MUS procedure should be performed carefully, considering the potential for postoperative de novo voiding dysfunction.
